Mission Pharmacal announced the launch of Hycofenix (hydrocodone bitartrate, pseudoephedrine HCl, guaifenesin) Oral Solution and Flowtuss (hydrocodone bitartrate, guaifenesin) Oral Solution for the relief of cough and cold symptoms in patients aged ≥18 years.
Hycofenix Oral Solution is the first approved combination of hydrocodone, pseudoephedrine, and guaifenesin. It is indicated to relieve cough, loosen respiratory secretions, and clear nasal congestion. Flowtuss Oral Solution is indicated to relieve cough and loosen respiratory secretions in patients who do not require a nasal decongestant.
Hydrocodone is a semisynthetic narcotic antitussive and analgesic with actions similar to that of codeine. It is believed to act directly on the cough center. Guaifenesin is an expectorant that promotes or facilitates the removal of secretions from the respiratory tract. It is thought to increase the volume and reduce the viscosity of secretions in the trachea and bronchi, increasing the efficiency of the cough reflex. Pseudoephedrine HCl is an orally active sympathomimetic that acts as a decongestant on the nasal mucosa. It produces peripheral effects similar to that of ephedrine and central effects similar to, but less intense than, amphetamines.
Hycofenix and Flowtuss Oral Solutions, both Schedule II controlled substances, are available in a black raspberry flavor. Both are available as 4 floz (118mL) and 16 floz (473mL) bottles.